A phase I study of the CSF1R inhibitor vimseltinib in combination with the PD-L1 inhibitor avelumab in patients with advanced sarcomaEvan Rosenbaum, Sandra P. D’Angelo, Martina Bradić et al.|ESMO Open|2025Cited by 6